Vanguard Group
DSGN icon

Vanguard Group’s Design Therapeutics DSGN Stock Holding History

Vanguard Group’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$15.3M Buy
1,630,910
+187,209
+13% +$1.47M ﹤0.01% 2749
2025
Q3 		$10.9M Sell
1,443,701
-27,873
-2% -$140K ﹤0.01% 2939
2025
Q2 		$4.96M Buy
1,471,574
+44,107
+3% +$165K ﹤0.01% 3222
2025
Q1 		$5.51M Sell
1,427,467
-3,278
-0.2% -$15.6K ﹤0.01% 3132
2024
Q4 		$8.83M Buy
1,430,745
+36,721
+3% +$213K ﹤0.01% 3023
2024
Q3 		$7.5M Buy
1,394,024
+97,236
+7% +$457K ﹤0.01% 3097
2024
Q2 		$4.34M Buy
1,296,788
+10,826
+0.8% +$42.2K ﹤0.01% 3313
2024
Q1 		$5.18M Buy
1,285,962
+288,803
+29% +$771K ﹤0.01% 3289
2023
Q4 		$2.64M Buy
997,159
+10,448
+1% +$23.9K ﹤0.01% 3503
2023
Q3 		$2.33M Buy
986,711
+3,437
+0.3% +$16K ﹤0.01% 3528
2023
Q2 		$6.19M Sell
983,274
-299,769
-23% -$1.83M ﹤0.01% 3203
2023
Q1 		$7.4M Sell
1,283,043
-278,657
-18% -$2.08M ﹤0.01% 3109
2022
Q4 		$16M Buy
1,561,700
+9,950
+0.6% +$135K ﹤0.01% 2732
2022
Q3 		$25.9M Buy
1,551,750
+271,706
+21% +$5.41M ﹤0.01% 2518
2022
Q2 		$17.9M Sell
1,280,044
-593,849
-32% -$8.02M ﹤0.01% 2692
2022
Q1 		$30.3M Buy
1,873,893
+3,391
+0.2% +$51.9K ﹤0.01% 2558
2021
Q4 		$40M Buy
1,870,502
+782,301
+72% +$13.4M ﹤0.01% 2476
2021
Q3 		$16M Sell
1,088,201
-117,765
-10% -$1.96M ﹤0.01% 2985
2021
Q2 		$24M Buy
1,205,966
+1,080,975
+865% +$27.3M ﹤0.01% 2753
2021
Q1 		$3.74M Buy
+124,991
New +$4.22M ﹤0.01% 3672

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group's DSGN Position: Q4 2025 in Review

Vanguard Group increased its Design Therapeutics (DSGN) stake by 13% in Q4 2025, buying an estimated $1.47M and bringing the position to 1,630,910 shares worth $15.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2749.

Vanguard Group first reported a position in DSGN in Q1 2021 and has held it in 20 quarters since. The position peaked at $40M in Q4 2021. 117 funds tracked by Wall St. Rank hold DSGN as of Q4 2025.

  • Vanguard Group held 1,630,910 shares of Design Therapeutics worth $15.3M as of Q4 2025.
  • Vanguard Group bought 187,209 Design Therapeutics shares in Q4 2025, an estimated $1.47M.
  • Design Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2749 holding.
  • Vanguard Group first reported a position in Design Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Vanguard Group's Design Therapeutics position peaked at $40M in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.